Pemphigus disease activity measurements: Pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score

JAMA Dermatology

Volumn 150, Issue 3, 2014, Pages 266-272

  Rahbar, Ziba ^a   Daneshpazhooh, Maryam ^a   Mirshams Shahshahani, Mostafa ^a   Esmaili, Nafiseh ^a   Heidari, Kazem ^b   Aghazadeh, Nessa ^a   Hejazi, Pardis ^a   Ghajarzadeh, Mahsa ^b   Chams Davatchi, Cheyda ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

DESMOGLEIN 1 ANTIBODY; DESMOGLEIN 3 ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ARTICLE; AUTOIMMUNE BULLOUS SKIN DISORDER INTENSITY SCORE; BLOOD LEVEL; BULLOUS SKIN DISEASE; CONTROLLED STUDY; CONVERGENT VALIDITY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERRATER RELIABILITY; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PEMPHIGUS DISEASE AREA INDEX; PEMPHIGUS VULGARIS; PEMPHIGUS VULGARIS ACTIVITY SCORE; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEX RATIO;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CROSS-SECTIONAL STUDIES; DESMOGLEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INCIDENCE; IRAN; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBSERVER VARIATION; PEMPHIGUS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SKIN DISEASES, VESICULOBULLOUS; YOUNG ADULT;

EID: 84896066762     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.8175     Document Type: Article

References (18)

1. Martin LK, Werth VP, Villaneuva EV, Murrell DF. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Acad Dermatol. 2011;64(5):903-908.
2. Rosenbach M, Murrell DF, Bystryn JC, et al. Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol. 2009;129(10):2404-2410.
3. Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Acad Dermatol. 2008;58(6):1043-1046.
4. Daniel BS, Hertl M, Werth VP, Eming R, Murrell DF. Severity score indexes for blistering diseases. Clin Dermatol. 2012;30(1):108-113.
5. Pfütz M, Niedermeier A, Hertl M, Eming R. Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus. Eur J Dermatol. 2007;17(1):4-11.
6. Behzad M, Möbs C, Kneisel A, et al. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. Br J Dermatol. 2012;166(4):844-852.
7. Chams-Davatchi C, Rahbar Z, Daneshpazhooh M, et al. Pemphigus vulgaris activity score and assessment of convergent validity. Acta Med Iran. 2013;51(4):224-230.
8. Chams-Davatchi C, Mortazavizadeh A, Daneshpazhooh M, et al. Randomized double blind trial of prednisolone and azathioprine, vs prednisolone and placebo, in the treatment of pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2012;27(10):1285-1292.
9. Harman KE, Seed PT, Grati, Bhogal BS, Challacombe SJ, Black MM. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol. 2001;144(4):775-780. (Pubitemid 32374780)
10. Amagai M, Tsunoda K, Zillikens D, Nagai T, Nishikawa T. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Acad Dermatol. 1999;40(2, pt 1):167-170. (Pubitemid 29072792)
11. Cheng SW, Kobayashi M, Kinoshita-Kuroda K, Tanikawa A, Amagai M, Nishikawa T. Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. Br J Dermatol. 2002;147(2):261-265.
12. Chams-Davatchi C, Valikhani M, Daneshpazhooh M, et al. Pemphigus: analysis of 1209 cases. Int J Dermatol. 2005;44(6):470-476. (Pubitemid 40867550)
13. Amagai M, Komai A, Hashimoto T, et al. Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. Br J Dermatol. 1999;140(2):351-357. (Pubitemid 29111371)
14. Bastuji-Garin S, Sbidian E. How to validate outcome instruments for pemphigus. J Invest Dermatol. 2009;129(10):2328-2330.
15. Abasq C, Mouquet H, Gilbert D, et al. ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. Arch Dermatol. 2009;145(5):529-535.
16. Kwon EJ, Yamagami J, Nishikawa T, Amagai M. Anti-desmoglein I autoantibodies in patients with pemphigus in remission. J Eur Acad Dermatol Venereol. 2008;22(9):1070-1075.
17. Schwartz RA, Monough PH, Lee BW. Toxic epidermal necrolysis, part II: the higher scores may have a similar scenario of prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Acad Dermatol. 2013;69(2):187.e1-16.
18. Sison-Fonacier L, Bystryn JC. Regional variations in antigenic properties of skin: a possible cause for disease-specific distribution of skin lesions. J Exp Med. 1986;164(6):2125-2130. (Pubitemid 17217993)